JLJialin Luo

Jialin Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jialin Luo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Guoping Cheng

    Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China

    2 shared publications
  • Linfeng Zheng

    Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China

    2 shared publications
  • Luying Liu

    Zhejiang cancer hospital 10 , Hangzhou, China

    2 shared publications
  • Yanru Feng

    Calgary, Alberta

    2 shared publications
  • Yuan Zhu

    Department of Radiation Oncology, Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), The Cancer Hospital of the University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou, China

    2 shared publications
  • Peng Liu

    Accelerator Division, Institute of High Energy Physics, Chinese Academy of Sciences, No. 19B Yuquan Road, Beijing 100049

    1 shared publication

Latest Publications

  • Open Access

    Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer

    by Yanru Feng, Jialin Luo, Peng Liu, Yuan Zhu, Guoping Cheng, Linfeng Zheng, Luying Liu

    Purpose: To evaluate the role of programmed death-ligand 1 (PD-L1) and mammalian target of rapamycin (mTOR) signaling pathway in locally advanced rectal cancer (LARC).Methods: Between February 2012 and February 2018, 103 patients with LARC treated by neoadjuvant chemoradiotherapy (neoCRT) and total mesorectal excision (TME) were included. PD-L1, mTOR and p-mTOR of pair-matched pre-neoCRT biopsies and post-neoCRT surgical tissue were evaluated by immunohistochemistry.Results: The mean combined positive score (CPS), tumor proportion score (TPS) and immune cell score (IC) of pre-neoCRT were 2.24 (0–70), 1.87 (0–70) and 0.67 (0–10), respectively. The mean CPS, TPS and IC of post-neoCRT were 2.19 (0–80), 1.38 (0–80) and 1.60 (0–20), respectively. Significant difference was observed in terms of IC between pre-neoCRT and post-neoCRT (p = 0.010). The 5-year disease-free survival (DFS) rate of the whole group was 62.4%. Multivariate analysis by Cox model indicated that pre-neoCRT TPS [hazard ratio (HR) 1.052, 95% confidence interval (CI) 1.020–1.086, p = 0.001] and post-neoCRT CPS (HR 0.733, 95% CI 0.555–0.967, p = 0.028) were associated with DFS. In the 89 patients without pathological complete response, p-mTOR and IC were upregulated after neoCRT.Conclusions: For patients with LARC treated by neoCRT and TME, p-mTOR and IC were upregulated after neoCRT. Pre-neoCRT TPS and post-neoCRT CPS were independent prognostic predictors of DFS.


  • Open Access

    Glasgow prognostic score and combined positive score for locally advanced rectal cancer

    by Yanru Feng, Jialin Luo, Peng Liu, Luying Liu, Yuan Zhu, Guoping Cheng, Linfeng Zheng

    Feng Y, et al. Ann Surg Treat Res. 2022 Mar;102(3):153-158. https://doi.org/10.4174/astr.2022.102.3.153